Avidity Biosciences, Inc. (RNA) earnings
RNA earnings moved a median of -0.95% by the close. Quarterly and annual RNA reports and results, each read against the price at its own news timestamp. Back to the RNA overview →
20 measured RNA earnings events.
Where these RNA earnings landedvs 18 measured RNA earnings reactions
| Middle 50% of RNA earnings reactions | -1.85% to +0.93% |
|---|---|
| Median reaction (to close) | -0.95% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 RNA earnings events with a measured close landed between -1.85% and +0.93%; 39% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Atrium Therapeutics Reports Third Quarter 2026 Financial Results | Press release | +0.20% | — | |
| Form 10-Q Atrium Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.20% | — | |
| Atrium Therapeutics Reports Second Quarter 2026 Financial Results | Press release | -0.16% | +5.16% | |
| Atrium Therapeutics Reports First Quarter 2026 Financial Results | Press release | +2.00% | -1.85% | |
| Form 10-K Avidity Biosciences, For: Dec 31 | SEC filing · Form 10-K | -0.06% | -0.23% | |
| Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Press release | +0.04% | +1.20% | |
| Form 10-Q Avidity Biosciences, For: Sep 30 | SEC filing · Form 10-Q | +0.04% | +1.20% | |
| Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Press release | -1.61% | -1.82% | |
| Form 10-Q Avidity Biosciences, For: Jun 30 | SEC filing · Form 10-Q | -1.61% | -1.82% | |
| Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights | Press release | +0.82% | -3.26% | |
| Form 10-Q Avidity Biosciences, For: Mar 31 | SEC filing · Form 10-Q | +0.82% | -3.26% | |
| Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights | Press release | +0.55% | +7.70% | |
| Form 10-K Avidity Biosciences, For: Dec 31 | SEC filing · Form 10-K | +0.55% | +7.70% | |
| Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Press release | -0.85% | +0.13% | |
| Form 10-Q Avidity Biosciences, For: Sep 30 | SEC filing · Form 10-Q | -0.85% | +0.13% | |
| Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights | Press release | -0.65% | -4.67% | |
| Form 10-Q Avidity Biosciences, For: Jun 30 | SEC filing · Form 10-Q | -0.65% | -4.67% | |
| Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights | Press release | +1.12% | -1.67% | |
| Form 10-Q Avidity Biosciences, For: Mar 31 | SEC filing · Form 10-Q | +1.12% | -1.67% | |
| Form 10-K Avidity Biosciences, For: Dec 31 | SEC filing · Form 10-K | +1.56% | -0.06% |
Keep exploring
More RNA: analyst actions → · SEC filings → · RNA overview →